Literature DB >> 23756667

Helicobacter pylori seropositivity is positively associated with colorectal neoplasms.

Kwan Woo Nam1, Myong Ki Baeg, Jung Hyun Kwon, Soung Hoon Cho, Soo Jin Na, Myung-Gyu Choi.   

Abstract

BACKGROUND/AIMS: Helicobacter pylori is a well known precursor to gastric cancer and gastric mucosa-associated lymphoid tissue lymphoma. This study was to determine whether H. pylori was associated with colorectal neoplasms in Korean subjects undergoing routine checkup.
METHODS: A total of 10,082 subjects underwent routine checkups from January 2004 to April 2005. A H. pylori IgG test and stool occult blood test were included in the routine checkup program. Colonoscopy was performed if the stool occult blood test was positive or under subject request. Patients who underwent colonoscopy and had histologically confirmed cases of colorectal neoplasms were designanted as the subject group and those without as the control group.
RESULTS: Of the 10,082 subjects, 597 had full colonoscopy. The results identified 9 colorectal carcinomas and 118 adenomas. H. pylori seropositivity was identified in 6 (66%) subjects with colorectal carcinoma, 81 (68.6%) with colorectal adenoma and 248 (52.8%) controls. Subjects having colorectal neoplasms had a significantly higher H. pylori seropositivity rate compared with the controls (OR 1.94, 95% CI 1.28-2.95). This remained significant after adjusting for age, sex, body mass index, HbA1c and total cholesterol (OR 1.90, 95% CI 1.23-2.93). Patients with distal neoplasms also had a significantly higher H. pylori seroposivity rate (OR 1.88, 95% CI 1.17-3.01) which persisted after multivariate adjustment (OR 1.79, 95% CI 1.10-2.94).
CONCLUSIONS: Subjects with colorectal neoplasms present an increased H. pylori seroprevalence compared with controls.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23756667     DOI: 10.4166/kjg.2013.61.5.259

Source DB:  PubMed          Journal:  Korean J Gastroenterol        ISSN: 1598-9992


  7 in total

1.  Clinicopathologic features of gastric cancer with synchronous and metachronous colorectal cancer in Korea: are microsatellite instability and p53 overexpression useful markers for predicting colorectal cancer in gastric cancer patients?

Authors:  Hee Jin Kim; Nayoung Kim; Yoon Jin Choi; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Hye Seung Lee; Sang-Hoon Ahn; Do Joong Park; Hyung Ho Kim; Il Tae Son; Sung-Bum Kang; Dong Ho Lee
Journal:  Gastric Cancer       Date:  2015-10-07       Impact factor: 7.370

Review 2.  Helicobacter pylori infection: new pathogenetic and clinical aspects.

Authors:  Krisztina Hagymási; Zsolt Tulassay
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

3.  Combination of Triple Therapy and Chronic PPI Use May Decrease Risk of Colonic Adenomatous Polyps in Helicobacter pylori Infection.

Authors:  Rina Zuniga; Josef Bautista; Katherine Sapra; Keith Westerfield; Susan Williams; Alexander M Sy
Journal:  Gastroenterol Res Pract       Date:  2015-05-12       Impact factor: 2.260

4.  Helicobacter pylori and colorectal cancer-A bacterium going abroad?

Authors:  Julia Butt; Meira Epplein
Journal:  PLoS Pathog       Date:  2019-08-08       Impact factor: 6.823

5.  Risk for Colorectal Neoplasia in Patients With Helicobacter pylori Infection: A Systematic Review and Meta-analysis.

Authors:  Da Sol Choi; Seung In Seo; Woon Geon Shin; Chan Hyuk Park
Journal:  Clin Transl Gastroenterol       Date:  2020-02       Impact factor: 4.396

6.  Association Between H. pylori Infection and Colorectal Polyps: A Meta-Analysis of Observational Studies.

Authors:  Depeng Lu; Mingyu Wang; Xiquan Ke; Qiangwu Wang; Jianchao Wang; Dapeng Li; Meng Wang; Qizhi Wang
Journal:  Front Med (Lausanne)       Date:  2022-01-18

7.  Association between Helicobacter pylori infection and the risk of colorectal cancer: A systematic review and meta-analysis.

Authors:  Yuling Zuo; Zhao Jing; Mingjiang Bie; Chunyan Xu; Xinyu Hao; Baoning Wang
Journal:  Medicine (Baltimore)       Date:  2020-09-11       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.